Faecalibacterium prausnitzii & Immune Checkpoint Inhibitors (ICIs)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Melanoma patients on PD-1 therapy who had an increased concentration of Faecalibacterium (Faecalibacterium prausnitzii) in their gut microbiome experienced longer progression-free survival compared to those with low abundance
Gopalakrishnan et al. 2018 Science 359: 97-103
Miller & Carson 2020 Gut Pathog 12: 43

Faecalibacterium prausnitzii produces butyrate with anti-inflammatory properties, potentially enhancing the efficacy of ICIs used for the treatment of breast cancer
Ren et al. 2025 Front Microbiol 16: 1591745

Among [Ipi…

References (Sources)

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
Gopalakrishnan et al. 2018 Science 359: 97-103
Mechanisms and microbial influences on CTLA-4 and PD-1-based immunotherapy in the treatment of cancer: a narrative review
Miller & Carson 2020 Gut Pathog 12: 43
Review
Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
Frankel et al. 2017
The role of the gut microbiota in shaping the tumor microenvironment and immunotherapy of breast cancer
Ren et al. 2025 Front Microbiol 16: 1591745
Review

AI Chat

11/5/2026

Chat with our artificial intelligence:

Start chat!

Faecalibacterium prausnitzii & Immune Checkpoint Inhibitors (ICIs)

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat